Pharmaceutical

HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines

HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.

May 10, 2025 - 06:00
HLS Therapeutics and Esperion partner to commercialise oral cardiovascular medicines
HLS Therapeutics has signed an agreement with Esperion Therapeutics for commercialising Nexletol and Nexlizet in Canada.
Read the original article

Tags:

Previous Article

5EU Q1 2024 versus 2025: Pricing shifts, HTA outcomes, and innovative drug trends

Next Article

Bavarian Nordic shares rise 7% following strong Q1 for vaccine sales

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure

Scientists document first-ever transmitted Alzheimer’s ...

Jan 30, 2024

MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor

MSD makes licence agreement with Hengrui Pharma for Lp(...

Mar 27, 2025

Gilead and Genesis partner to create novel therapies using AI

Gilead and Genesis partner to create novel therapies us...

Sep 12, 2024